Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX – Get Free Report) saw a large decline in short interest in the month of April. As of April 15th, there was short interest totalling 115,600 shares, a decline of 57.0% from the March 31st total of 268,900 shares. Based on an average daily volume of 111,900 shares, the short-interest ratio is presently 1.0 days. Approximately 2.6% of the company’s shares are sold short.
Salarius Pharmaceuticals Stock Performance
Shares of SLRX remained flat at $0.50 during mid-day trading on Friday. The stock had a trading volume of 4,071 shares, compared to its average volume of 39,317. The business has a 50-day simple moving average of $0.56 and a 200-day simple moving average of $0.62. Salarius Pharmaceuticals has a 52-week low of $0.43 and a 52-week high of $2.31.
Salarius Pharmaceuticals (NASDAQ:SLRX – Get Free Report) last released its quarterly earnings results on Friday, March 22nd. The company reported ($0.22) earnings per share for the quarter, beating the consensus estimate of ($1.01) by $0.79. Research analysts forecast that Salarius Pharmaceuticals will post -26.8 EPS for the current fiscal year.
Hedge Funds Weigh In On Salarius Pharmaceuticals
Salarius Pharmaceuticals Company Profile
Salarius Pharmaceuticals, Inc, a clinical-stage biotechnology company, focuses on developing treatments for cancers with unmet medical need. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma.
Read More
- Five stocks we like better than Salarius Pharmaceuticals
- Low PE Growth Stocks: Unlocking Investment Opportunities
- MarketBeat Week in Review – 4/22 – 4/26
- What is a Dividend King?
- 3 Stocks Leading the U.S. Agriculture Comeback
- What Are the FAANG Stocks and Are They Good Investments?
- How to Use Put Debit Spreads to Profit From Falling Stocks
Receive News & Ratings for Salarius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Salarius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.